Skip to main content
. 2019 Feb 7;23(4):2801–2812. doi: 10.1111/jcmm.14188

Figure 1.

Figure 1

LMK235 reduces high blood pressure in angiotensin II‐induced hypertensive mice and spontaneously hypertensive rats (SHRs). (A‒B) Systolic blood pressures were measured in vehicle‐treated control, vehicle‐treated angiotensin II‐infusion (Ang II) and LMK235‐treated angiotensin II‐infusion (Ang II + LMK235) mice (n = 8 each). Administration of LMK235 was started 1 wk after angiotensin II‐infusion in mice. Mice were given LMK235 daily (A; 1 mg/kg/d, B; 3 mg/kg/d). ***P < 0.001 vs vehicle‐treated control; ### P < 0.001 vs vehicle‐treated angiotensin II‐infusion mice. (C) Systolic blood pressures were determined in WKY control rats, LMK235‐treated WKY rats, vehicle‐treated SHRs and LMK235‐treated SHRs (n = 4 each). LMK235 was administered every 3 d, and systolic blood pressures were measured daily. ***P < 0.001 (vehicle‐treated WKY control vs vehicle‐treated SHRs, black); # P < 0.05, ## P < 0.01 and ### P < 0.001 (vehicle‐treated SHRs vs LMK235‐treated SHRs, red); NS indicates not significant